OncoIndustry
Steven O’Day Opens New Opportunities in the BOT BAL Immunotherapy Program
Steven O’Day/LinkedIn

Steven O’Day Opens New Opportunities in the BOT BAL Immunotherapy Program

Steven O’Day, Chief Medical Officer at Agenus, shared on LinkedIn:

“We are looking for experienced Clinical Development talent to lead and advance our BOT BAL Immunotherapy Program!

BOT BAL makes ‘Cold’ Tumors ‘Hot‘ and we are rapidly moving from late stage disease to our Global Phase 3 ROBBIN Neoadjuvant Colon Cancer Trial!

Reach out if you are interested in joining our extraordinary team as we advance a new revolution of Immuno-Oncology!”

You may also be interested in: Three BOT/BAL Studies in Colorectal Cancer and Sarcoma at ESMO Congress 2026

Steven O’Day Opens New Opportunities in the BOT BAL Immunotherapy Program

Agenus Balstilimab BOT/BAL BOTBAL botensilimab cancer cancer immunotherapy Colon cancer colorectal cancer immuno-oncology immunotherapy Microsatellite-Stable Colorectal Cancer MSS colorectal cancer neoadjuvant immunotherapy neoadjuvant therapy OncoDaily Oncology Phase 3 Clinical Trial ROBBIN trial solid tumors Steven O'Day